On December 14, we signed a framework agreement with the Gustave Roussy Institute for projects in oncology and immuno-oncology. This is a long-term strategic collaboration – four years renewable – which aims to optimize therapeutic management of several cancers. 

Ranked as Europe’s leading oncology center and the third largest in the world, the Gustave Roussy Institute is a global center of expertise entirely dedicated to cancer patients. Based near Paris, it welcomes nearly 50,000 patients each year and develops an integrated approach between research, care and teaching.

To date, thanks to this partnership, five projects in adult and pediatric oncology have been identified and will be launched shortly. They concern indications of interest developed by Servier and which still have unmet needs. The agreement is also accompanied by early phase clinical trials with innovative compounds from Servier’s oncology pipeline that will be conducted by Gustave Roussy.

“This collaboration allows combining the expertise of Servier and Gustave Roussy, with the common objective of initiating ambitious R&D projects for purposes of developing therapeutic innovations targeting resistant cancers, such as certain acute myeloid leukemias in adults, and treatments targeting cancers with high unmet needs, such as certain brain tumors in children.”

Prof. Angelo Paci, Program Leader Oncology and Immuno-onco at Servier

“It is the culmination of a long-standing collaboration that will eventually be reflected in the Paris-Saclay Cancer Cluster. The first research projects in hematology, immuno-oncology and pediatrics illustrate the scope and momentum that this agreement will further boost our collaboration.”

Prof. Fabrice Barlesi, CEO of Gustave Roussy